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Human embryonic stem cell (hESC) and reprogrammed/induced
pluripotent stem cell (iPSC) research is becoming the ‘‘ﬂavor of
the month’’ for downstream applications such as drug screening,
disease modeling, and future regenerative medicine and cell thera-
pies [1–4]. Pluripotency (the ability to give rise to any cell type
of the three germ layers: mesoderm, ectoderm, and endoderm) is
the deﬁning feature of hESCs and iPSCs [5]. In vivo teratoma
formation in immune-compromised mice is the ‘‘gold-standard’’
assay to deﬁne bona ﬁde pluripotent stem cells capable of gener-
ating tumoral disorganized structures containing tissues repre-
senting the three germ layers [5, 6]. Despite the importance of
teratoma assay as an extended screen for the pluripotency of
hESCs and iPSCs and as in vivo assay to explore molecular and
cellular mechanisms underlying the biology of human teratomas
and their transition to teratocarcinomas, there are no standard
procedures for performing this assay [5–7]. Different studies on
hESCs have correlated the site of implantation with the efﬁ-
ciency of teratoma formation and histology tissue composition
[6, 8]. However, limited data are available regarding the tera-
toma development latency. More importantly, no study so far
has compared side-by-side the efﬁciency, latency, and histologi-
cal tumor composition of hESCs- and iPSCs-derived teratomas.
In addition, a new generation of immunodeﬁcient mice has been
developed: the NOD/SCID IL2Rc
 /  mouse. This strain carries
a IL2Rc-chain deﬁciency that blocks signaling through multiple
cytokine receptors leading to many innate immune defects [9,
10]. The non obese diabetic/severe combined immune-deﬁcient
(NOD/SCID) IL2Rc
 /  strain facilitates engraftment and tumor
formation and does not develop thymic lymphoma, ensuring a
longer lifespan of inoculated mice.
Here, we followed the improved teratoma protocol previ-
ously developed by Prokhorova et al. [6, 11–13] to transplant
side-by-side as few as 1   10
6 of either fully characterized un-
differentiated hESCs or iPSCs in 6- to 8-week-old non obese di-
abetic/severe combined immune-deﬁcient (NOD/SCID)
IL2Rc
 /  mice [11, 13–15]. The following hESC lines were
used: H9, H1, AND1, AND2, AND3, HS181, and ECAT. The
following iPSC lines were used: MSHU-001, iAND4, CB-
CD34þ iPSC1, and CB-CD34þ iPSC2. These lines have been
fully characterized and deposited according to Spanish Legisla-
tion at The Spanish Stem Cell Bank (http://www.isciii.es/
htdocs/terapia/terapia_lineas.jsp) [16]. Brieﬂy, cells were resus-
pended in phosphate buffered saline (PBS) supplemented with
30% matrigel (Becton Dickinson, San Jose, CA, http://
www.bd.com) [6] and transplanted subcutaneously (200 ll vol-
ume) or by intratesticular injection (60 ll volume). Figure 1A
depicts the experimental strategy used. We then analyzed efﬁ-
ciency, latency, and histological tumor composition. In hESCs,
the rate of teratoma formation was 81% subcutaneously versus
94% intratesticularly (n ¼ 30 mice; Fig. 1B). However, the in-
tratesticular injection, despite showing higher efﬁciency of tera-
toma formation, displayed a slightly longer latency (66 vs. 59
days; p-value > 0.05). There were no site-speciﬁc differences
in the teratoma composition at the histological level (Fig. 1C).
Interestingly, when iPSCs were transplanted the rate of tera-
toma formation was 100% (n ¼ 16 mice), regardless the type of
injection. More importantly, iPSCs seem more aggressive in
vivo as the latency was shortened 52% (from 59 days to
31 days) upon subcutaneous injection and 26% (from 66 days
to 49 days) upon intratesticular injection. As with hESCs, no
differences in teratoma composition were observed either.
To the best of our knowledge, this is the ﬁrst study compar-
ing side-by-side the efﬁciency, latency, and teratoma composi-
tion between hESCs and iPSCs. We found clear differences in
the efﬁciency and latency but not in the teratoma histological
composition. Further experiments are still demanded to gain
insights into the higher aggressiveness in vivo of iPSCs as com-
pared with hESCs. Ploidy, analyzed by conventional G-banding
karyotype, could not explained these differences because all but
two pluripotent stem cell lines were euploid: the aneuploid lines
were one hESC (AND1) and one iPSC (iAND4). It is worth
emphasizing, however, that karyotype analysis is not a high-re-
solution technique detecting ﬁne genomic aberrations, with a
euploid karyotype not being therefore indicative of an overall
cellular genomic stability. Whether or not speciﬁc tiny genomic
insults (detectable by high-resolution methods such as compar-
ative genomic hybridazation (CGH)-arrays and single-nucleo-
tide polymorphism analysis) or epigenetic differences may
explain the higher aggressiveness in vivo of iPSCs still needs to
be elucidated. We envision that these data may be useful not
only for stem cells scientists addressing pluripotency issues and
studying mechanisms underlying speciﬁc germ-layer/tissue
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vivo models for germ cell tumors.
ACKNOWLEDGMENTS
We thank Prof. Paco Nogales at The Department of Pathology,
University of Granada for his helpful assistance with diagnosis and
histology. P.M.’s group is supported by: CICE (P08-CTS-3678 to
P . M . )d el aJ u n t ad eA n d a l u c ı ´a; the FIS to P.M. (PI070026), to
C.B. (CP07/0059), and to P.J.R. (CP09/0063); the MINICC to
P.M. (PLE-2009-0111) and the Marie Curie IIF to V.R.-M. (PIIF-
GA-2009-236430). J.L.G.-P.’s group is supported by ISCIII-CSJA
(EMER07/056), by a Marie Curie IRG action (FP7-PEOPLE-
2007-4-3-IRG), by CICE (P09-CTS-4980) from Junta de Andalu-
cı ´a, by Proyectos de Investigacio ´ne nS a l u dP I - 0 0 2f r o mJ u n t ad e
Andalucı ´a, and by the FIS (CP07/00065 and PI08171).
DISCLOSURE OF POTENTIAL CONFLICTS
OF INTEREST
The authors indicate no potential conﬂict of interest.
REFERENCES
1 Bueno C, Catalina P, Melen GJ et al. Etoposide induces MLL rear-
rangements and other chromosomal abnormalities in human embryonic
stem cells. Carcinogenesis 2009;30:1628–1637.
Figure 1. Human iPSCs form
teratomas faster and with higher
efﬁciency than hESCs regardless
the site of injection. (A): Car-
toon summarizing the experi-
mental design. (B): Table
summarizing the efﬁciency, la-
tency, and histological analysis
of the teratomas developed from
both human ESCs and human
iPSCs upon either subcutaneous
or intratesticular transplantation.
(C): Histological analysis of ter-
atomas derived from both
hESCs and iPSCs upon subcuta-
neous or intratesticular trans-
plantation reveal similar tissue
composition. The presence of
mesodermal tissues is deﬁned by
teratoma sections containing car-
tilage and positive for both
smooth muscle actin and mela-
nin. The presence of ectodermal
tissues was scored as teratoma
sections that stained positive for
b-III tubulin and presence of
neural rosettes. Endoderm was
deﬁned as teratoma sections that
stained positive for a-fetoprotein
and pan-cytokeratin. The study
was approved by the Andalusian
and Spanish Embryo and Cellu-
lar Reprogramming Ethical
Institutional review Board. Ani-
mal protocols were approved by
the Local University Hospital
Council On Animal Care and
Experimentation. Abbreviations:
ESCs, embryonic stem cells;
iPSCs, reprogrammed/induced
pluripotent stem cells.
Gutierrez-Aranda, Ramos-Mejia, Bueno et al. 1569
www.StemCells.com2 Bueno C, Garcia-Castro J, Montes R et al. Human embryonic stem
cells: A potential system for modeling infant leukemia harboring
MLL-AF4 fusion gen. Drug Dis Today: Dis Models 2008;4:53–59.
3 Menendez P, Bueno C, Wang L. Human embryonic stem cells: A jour-
ney beyond cell replacement therapies. Cytotherapy 2006;8:530–541.
4 Menendez P, Bueno C, Wang L et al. Human embryonic stem cells:
Potential tool for achieving immunotolerance? Stem Cell Rev 2005;1:
151–158.
5 Przyborski SA. Differentiation of human embryonic stem cells after trans-
plantation in immune-deﬁcient mice. Stem Cells 2005;23:1242–1250.
6 Prokhorova TA, Harkness LM, Frandsen U et al. Teratoma formation
by human embryonic stem cells is site-dependent and enhanced by the
presence of matrigel. Stem Cells Dev 2009;18:47–54.
7 Muller FJ, Goldmann J, Loser P et al. A call to standardize teratoma
assays used to deﬁne human pluripotent cell lines. Cell Stem Cell
2010;6:412–414.
8 Cooke MJ, Stojkovic M, Przyborski SA. Growth of teratomas derived
from human pluripotent stem cells is inﬂuenced by the graft site.
Stem Cells Dev 2006;15:254–259.
9 Bueno C, Montes R, de la Cueva T et al. Intra-bone marrow trans-
plantation of human CD34(þ) cells into NOD/LtSz-scid IL-2rgamma
(null) mice permits multilineage engraftment without previous irradia-
tion.Cytotherapy 2010;12:45–49.
10 Shultz LD, Lyons BL, Burzenski LM et al. Human lymphoid and mye-
loid cell development in NOD/LtSz-scid IL2R gamma null mice
engrafted with mobilized human hemopoietic stem cells. J Immunol
2005;174:6477–6489.
11 Catalina P, Bueno C, Montes R et al. Genetic stability of human embryonic
stem cells: A ﬁrst-step toward the development of potential hESC-based
systems for modeling childhood leukemia. Leuk Res 2009;33:980–990.
12 Cortes JL, Sanchez L, Catalina P et al. Whole-blastocyst culture
followed by laser drilling technology enhances the efﬁciency of
inner cell mass isolation and embryonic stem cell derivation from
good- and poor-quality mouse embryos: New insights for deriva-
tion of human embryonic stem cell lines. Stem Cells Dev 2008;
17:255–267.
13 Cortes JL, Sanchez L, Ligero G et al. Mesenchymal stem cells facili-
tate the derivation of human embryonic stem cells from cryopreserved
poor-quality embryos. Hum Reprod 2009;24:1844–1851.
14 Barroso-delJesus A,Romero-Lopez C, Lucena-Aguilar G et al. Embry-
onic stem cell-speciﬁc miR302–367 cluster: Human gene structure and
functional characterization of its core promoter. Mol Cell Biol 2008;
28:6609–6619.
15 Catalina P, Montes R, Ligero G et al. Human ESCs predisposition to
karyotypic instability: Is a matter of culture adaptation or differential
vulnerability among hESC lines due to inherent properties? Mol Can-
cer 2008;7:76–84.
16 International Stem Cell Banking Initiative.Consensus guidance for
banking and supply of human embryonic stem cell lines for research
purposes. Stem Cell Rev 2009;5:301–314.
1570 Teratoma Development from iPSCs and hESCs